Xospata

(Gilteritinib)

Xospata

Drug updated on 11/15/2023

Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • To treat refractory or relapsed acute myeloid leukemia in adults with a FLT3 mutation as detected by an FDA-approved test.